FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Bas van Rhijn

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Co-author Network

Publications

TOP 3
Morgan Rouprêt; Richard Sylvester; Bas W G van Rhijn; Richard Zigeuner; Marko Babjuk; Andreas Böhle; Max Burger; Eva Compérat; Nigel Cowan; Eero Kaasinen; Joan Palou; Shahrokh F Shariat
European guidelines on upper tract urothelial carcinomas: 2013 update.
Laura S Mertens; Bas W G van Rhijn; Erik Vegt; Wouter V Vogel; André M Bergman; Annemarie Fioole-Bruining; J Martijn Kerst; Simon Horenblas
FDG-Positron Emission Tomography/Computerized Tomography for Monitoring the Response of Pelvic Lymph Node Metastasis to Neoadjuvant Chemotherapy for Bladder Cancer.
R P Meijer; Wim Meinhardt; Jakko A Nieuwenhuijzen; Henk G van der Poel; Bas W G van Rhijn; E van Werkhoven; A M Bergman; Axel Bex; J Martijn Kerst; Simon Horenblas
Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Bas van Rhijn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Morgan Rouprêt; Richard Sylvester; Bas W G van Rhijn; Richard Zigeuner; Marko Babjuk; Andreas Böhle; Max Burger; Eva Compérat; Nigel Cowan; Eero Kaasinen; Joan Palou; Shahrokh F Shariat
European guidelines on upper tract urothelial carcinomas: 2013 update.
European urology 2013;63(6):1059-71.
2013: Laura S Mertens; Bas W G van Rhijn; Erik Vegt; Wouter V Vogel; André M Bergman; Annemarie Fioole-Bruining; J Martijn Kerst; Simon Horenblas
FDG-Positron Emission Tomography/Computerized Tomography for Monitoring the Response of Pelvic Lymph Node Metastasis to Neoadjuvant Chemotherapy for Bladder Cancer.
The Journal of urology 2013;189(5):1687-91.
2013: R P Meijer; Wim Meinhardt; Jakko A Nieuwenhuijzen; Henk G van der Poel; Bas W G van Rhijn; E van Werkhoven; A M Bergman; Axel Bex; J Martijn Kerst; Simon Horenblas
Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2013;39(4):365-71.
2013: Sean C Skeldon; Theodorus H Van Der Kwast; Bas W G van Rhijn; Melyssa Aronson; Bharati Bapat; Peter Bostrom; Jim Catto; Zane Cohen; Andrew Evans; Neil E Fleshner; Steven Gallinger; Sally Hanna; Spring Holter; Michael A Jewett; Cynthia Kuk; Aaron Pollett; Kara Semotiuk; Shahrokh F Shariat; Alexandre R Zlotta
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
European urology 2013;63(2):379-85.
2013: Ashish M Kamat; Peter E Clark; Michael Droller; Jason R Gee; Nicholas Hegarty; Paul K Hegarty; Lawrence C Jenkins; Yair Lotan; Bernd J Schmitz-Dräger; Shahrokh F Shariat; Robert S Svatek; Bas W G van Rhijn; evanguelos xylinas; Pierre I Karakiewicz
ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers.
European urology 2013;63(1):4-15.
2012: Laura S Mertens; Bas W G van Rhijn; Harm van Tinteren; Andries M Bergman; J Martijn Kerst; Richard P Meijer; Simon Horenblas
Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?
The Journal of urology 2012;188(4):1108-13.
2012: Bas W G van Rhijn; André N Vis; Tahlita C M Zuiverloon; Ellen C Zwarthoff; Sultan S Alkhateeb; Chris H Bangma; Bharati Bapat; Peter J Bostrom; Neil E Fleshner; Michael A S Jewett; Liyang Liu; Madelon N M van der Aa; Theo H van der Kwast; Alexandre R Zlotta
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
BJU international 2012;110(8):1169-76.
2012: Polat Turker; Bas W G van Rhijn; Marcelo L Wroclawski; Peter J Bostrom; Andy Evans; Antonio Finelli; Neil E Fleshner; Michael A Jewett; Hannes Kortekangas; Cynthia Kuk; Theo Vander Kwast; Matti Laato; Tuomas Mirtti; Joan Sweet; Alexandre R Zlotta
Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.
BJU international 2012;110(6):804-11.
2012: Bas W G van Rhijn
Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer.
Urologic oncology 2012;30(4):518-23.
2012: Richard P Meijer; Bas W G van Rhijn
A plea for long-term surveillance in bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer.
European urology 2012;61(3):508-9.
2011: Bas W G van Rhijn
Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
BJU international 2011;108(7):1123-4.
2011: Carmen Mir; Hiroshi Miyamoto; Juan Morote; Shahrokh F Shariat; Sean Skeldon; Rati Vajpeyi; Theodorus H van der Kwast; Bas W G van Rhijn; Jorge Yao; Sultan Alkhateeb; Raheela Ashfaq; Peter Bostrom; Andrew Evans; Neil Fleshner; Sally Hanna; Michael Jewett; Cynthia Kuk; Yair Lotan; Ed Messing; Alexandre R Zlotta
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study.
BJU international 2011;108(1):24-30.
2011: David M Kakiashvili; Bas W G van Rhijn; Greg Trottier; Michael A S Jewett; Neil Fleshner; Antonio Finelli; Julian Azuero; Chris H Bangma; Rati Vajpeyi; Sultan Alkhateeb; Sally Hanna; Alex Kostynsky; Cynthia Kuk; Theodorus H Van Der Kwast; Alexandre R Zlotta
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
BJU international 2011;107(4):540-6.
2010: Peter J Boström; Sultan Alkhateeb; Bas W G van Rhijn; Cynthia Kuk; Alexandre R Zlotta
Optimal timing of radical cystectomy in T1 high-grade bladder cancer.
Expert review of anticancer therapy 2010;10(12):1891-902.
2010: Bas W G van Rhijn; Tahlita C M Zuiverloon; André N Vis; François Radvanyi; Geert J L H van Leenders; Bert C M Ooms; Wim J Kirkels; Gina A Lockwood; Egbert R Boevé; Adriaan C Jöbsis; Ellen C Zwarthoff; Theo Van der Kwast
Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer.
European urology 2010;58(3):433-41.
2010: Sultan S Alkhateeb; Bas W G van Rhijn; Antonio Finelli; Theodorus van der Kwast; Andrew Evans; Sally Hanna; Rati Vajpeyi; Neil Fleshner; Michael A S Jewett; Alexandre R Zlotta
Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
The Journal of urology 2010;184(1):81-6.
2010: Bas W G van Rhijn; Theo Van der Kwast; David M Kakiashvili; Neil Fleshner; Madelon N M van der Aa; Sultan Alkhateeb; Chris H Bangma; Michael A S Jewett; Alexandre R Zlotta
Pathological stage review is indicated in primary pT1 bladder cancer.
BJU international 2010;106(2):206-11.
2010: Bas W G van Rhijn; Geert J L H van Leenders; Bert C M Ooms; Wim J Kirkels; Alexandre R Zlotta; Egbert R Boevé; Adriaan C Jöbsis; Theo Van der Kwast
The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.
European urology 2010;57(6):1052-7.
2010: Alexandre R Zlotta; Samuel M Cohen; Colin Dinney; Michael Droller; Theo Van der Kwast; Bas W G van Rhijn; Bernard H Bochner; Gilad Ameil; Michael A S Jewett
BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer.
Urologic oncology 2010;28(3):329-33.
2010: Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo Van der Kwast; Ellen C Zwarthoff
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
PloS one 2010;5(11):e13821.
2010: Madelon N M van der Aa; Ewout W Steyerberg; Chris Bangma; Bas W G van Rhijn; Ellen C Zwarthoff; Theo Van der Kwast
Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.
The Journal of urology 2010;183(1):76-80.
2009: Bas W G van Rhijn; Maximilian Burger; Yair Lotan; Eduardo Solsona; Christian G Stief; Richard J Sylvester; J Alfred Witjes; Alexandre R Zlotta
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.
European urology 2009;56(3):430-42.
2009: Esther W de Bekker-Grob; Madelon N M van der Aa; Ellen C Zwarthoff; Marinus Eijkemans; Bas W G van Rhijn; Theo Van der Kwast; Ewout W Steyerberg
Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
BJU international 2009;104(1):41-7.
2008: Bas W G van Rhijn
Considerations on the use of urine markers for bladder cancer.
European urology 2008;53(5):880-1.
2005: Johanna M M van Oers; Irene Lurkin; Antonius J A van Exsel; Yvette Nijsen; Bas W G van Rhijn; Madelon N M van der Aa; Ellen C Zwarthoff
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7743-8.
2005: Madelon N M van der Aa; Geert J L H van Leenders; Ewout W Steyerberg; Bas W G van Rhijn; Adriaan C Jöbsis; Ellen C Zwarthoff; Theo Van der Kwast
A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation.
Human pathology 2005;36(9):981-6.
2005: Bas W G van Rhijn; Henk G van der Poel; Theo Van der Kwast
Urine markers for bladder cancer surveillance: a systematic review.
European urology 2005;47(6):736-48.
2004: Bas W G van Rhijn; Theo Van der Kwast; André N Vis; Wim J Kirkels; Egbert R Boevé; Adriaan C Jöbsis; Ellen C Zwarthoff
FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.
Cancer research 2004;64(6):1911-4.
2004: Barthold Ph Schrier; Maarten P Hollander; Bas W G van Rhijn; Lambertus A L M Kiemeney; J Alfred Witjes
Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy.
European urology 2004;45(3):292-6.
2003: Bas W G van Rhijn; André N Vis; Theo Van der Kwast; Wim J Kirkels; François Radvanyi; Engelbert C M Ooms; Dominique K Chopin; Egbert R Boevé; Adriaan C Jöbsis; Ellen C Zwarthoff
Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10):1912-21.
2003: Bas W G van Rhijn; Marij Smit; Danielle van Geenen; Arendjan Wijnmaalen; Wim J Kirkels; Theo Van der Kwast; Vibeke Kuenen-Boumeester; Ellen C Zwarthoff
Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy.
European urology 2003;43(4):369-73.
2003: Bas W G van Rhijn; Irene Lurkin; Dominique K Chopin; Wim J Kirkels; Jean Paul Thiery; Theo Van der Kwast; François Radvanyi; Ellen C Zwarthoff
Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):257-63.
2002: Bas W G van Rhijn; Angela van Tilborg; Irene Lurkin; Jacky Bonaventure; Annie de Vries; Jean Paul Thiery; Theo Van der Kwast; Ellen C Zwarthoff; François Radvanyi
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
European journal of human genetics : EJHG 2002;10(12):819-24.
2002: Bas W G van Rhijn; Rodolfo Montironi; Ellen C Zwarthoff; Adriaan C Jöbsis; Theo Van der Kwast
Frequent FGFR3 mutations in urothelial papilloma.
The Journal of pathology 2002;198(2):245-51.
2002: André N Vis; Bas W G van Rhijn; Marinus A Noordzij; Fritz H Schröder; Theo Van der Kwast
Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.
The Journal of pathology 2002;197(2):148-54.
2002: André N Vis; A van der Gaast; Bas W G van Rhijn; T K Catsburg; C Schmidt; G H J Mickisch
A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy.
Cancer chemotherapy and pharmacology 2002;49(4):342-5.
2001: Bas W G van Rhijn; Irene Lurkin; Wim J Kirkels; Theo Van der Kwast; Ellen C Zwarthoff
Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial.
Cancer 2001;92(4):768-75.
2001: C Billerey; Dominique Chopin; M H Aubriot-Lorton; David Ricol; Sixtina Gil-Diez-De-Medina; Bas W G van Rhijn; Marie-Pierre Bralet; Marie-Aude Lefrere-Belda; J B Lahaye; Claude C Abbou; Jacky Bonaventure; Elie Serge Zafrani; Theo Van der Kwast; Jean Paul Thiery; François Radvanyi
Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
The American journal of pathology 2001;158(6):1955-9.
2001: Bas W G van Rhijn; Irene Lurkin; François Radvanyi; Wim J Kirkels; Theo Van der Kwast; Ellen C Zwarthoff
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
Cancer research 2001;61(4):1265-8.
2000: Henk G van der Poel; Bas W G van Rhijn; Pim Peelen; Frans M J Debruyne; Mathilde E Boon; Jack A Schalken
Consecutive quantitative cytology in bladder cancer.
Urology 2000;56(4):584-8.
2000: Bas W G van Rhijn; Henk G van der Poel; Mathilde E Boon; Frans M J Debruyne; Jack A Schalken; J Alfred Witjes
Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt.
Urology 2000;55(3):363-7.